ET Pharma

Gland Pharma inks strategic CDMO deal with global pharma firm, eyes $90-100 million annual revenue

Aug 10, 2026, 1:02 AM

Translate article text

Choose a language and wait for the translated text.

The agreement covers 55 SKUs to be manufactured across three Gland Pharma sites, with scope for additional products to be added. Once the portfolio is fully commercialised, the agreement is expected to have an annualised revenue potential of approximately $90 million-$100 million.